NASDAQ:IDXX - IDEXX Laboratories Stock Price, Price Target & More

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories announced that its Board of Directors has authorized a share buyback plan on Sunday, June 4th 2017, which permits the company to repurchase 3,000,000 outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company's management believes its shares are undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings data on Friday, May, 4th. The company reported $1.01 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.09. The company had revenue of $537.60 million for the quarter, compared to the consensus estimate of $525.14 million. IDEXX Laboratories had a net margin of 13.87% and a negative return on equity of 530.24%. The company's revenue for the quarter was up 16.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.77 earnings per share. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories updated its FY18 earnings guidance on Friday, May, 4th. The company provided EPS guidance of $4.06-4.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.11. The company issued revenue guidance of +12-14% to ~$2.205-2.245 billion, compared to the consensus revenue estimate of $2.22 billion.

7 brokers have issued twelve-month price objectives for IDEXX Laboratories' shares. Their predictions range from $200.00 to $228.00. On average, they expect IDEXX Laboratories' stock price to reach $216.50 in the next twelve months. View Analyst Ratings for IDEXX Laboratories.

Some companies that are related to IDEXX Laboratories include IPSEN S A/S (IPSEY), Neogen (NEOG), Immunomedics (IMMU), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX) and Vermillion (VRML).

Headlines about IDXX stock have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. IDEXX Laboratories earned a coverage optimism score of 0.22 on Accern's scale. They also assigned news stories about the company an impact score of 44.90 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

IDEXX Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.61%), Bamco Inc. NY (5.15%), Blair William & Co. IL (1.87%), Neuberger Berman Group LLC (1.86%), Northern Trust Corp (1.16%) and Old Mutual Global Investors UK Ltd. (1.08%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bamco Inc. NY, Blair William & Co. IL, Millennium Management LLC, Federated Investors Inc. PA, Natixis, American Century Companies Inc. and Old Mutual Global Investors UK Ltd.. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jonathan W Ayers, Rebecca M Henderson and William T End. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, AGF Investments Inc., Prudential Financial Inc., OppenheimerFunds Inc., Westfield Capital Management Co. LP, Wells Fargo & Company MN, Select Equity Group L.P. and Chicago Capital LLC. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $225.38.

IDEXX Laboratories has a market capitalization of $19.80 billion and generates $1.97 billion in revenue each year. The company earns $263.14 million in net income (profit) each year or $3.28 on an earnings per share basis. IDEXX Laboratories employs 7,600 workers across the globe.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]